156 related articles for article (PubMed ID: 36593169)
1. The Current State of Knowledge About Evolution of Multiple Myeloma to Plasma Cell Leukemia.
Jurczyszyn A; Olszewska-Szopa M; Vesole DH
Clin Lymphoma Myeloma Leuk; 2023 Mar; 23(3):188-193. PubMed ID: 36593169
[TBL] [Abstract][Full Text] [Related]
2. Clinicopathological and laboratory parameters of plasma cell leukemia among Indian population.
Dubey H; Goel H; Verma S; Gupta S; Tanwar K; Rahul E; Kapoor G; Vasantharaman J; Ranjan A; Tanwar P; Chopra A
Am J Blood Res; 2022; 12(6):190-195. PubMed ID: 36742277
[TBL] [Abstract][Full Text] [Related]
3. Clinical and cytogenetic characteristics of primary and secondary plasma cell leukemia under the new IMWG definition criteria: a retrospective study.
Guan J; Ma J; Chen B
Hematology; 2023 Dec; 28(1):2254556. PubMed ID: 37732631
[TBL] [Abstract][Full Text] [Related]
4. Proteome alterations associated with transformation of multiple myeloma to secondary plasma cell leukemia.
Zatula A; Dikic A; Mulder C; Sharma A; Vågbø CB; Sousa MML; Waage A; Slupphaug G
Oncotarget; 2017 Mar; 8(12):19427-19442. PubMed ID: 28038447
[TBL] [Abstract][Full Text] [Related]
5. Bortezomib-based Regimens Improve the Outcome of Patients with Primary or Secondary Plasma Cell Leukemia: A Retrospective Cohort Study.
Wang H; Zhou H; Zhang Z; Geng C; Chen W
Turk J Haematol; 2020 May; 37(2):91-97. PubMed ID: 31769277
[TBL] [Abstract][Full Text] [Related]
6. The Cytogenetic Profile of Primary and Secondary Plasma Cell Leukemia: Etiopathogenetic Perspectives, Prognostic Impact and Clinical Relevance to Newly Diagnosed Multiple Myeloma with Differential Circulating Clonal Plasma Cells.
Papadhimitriou SI; Terpos E; Liapis K; Pavlidis D; Marinakis T; Kastritis E; Dimopoulos MA; Tsitsilonis OE; Kostopoulos IV
Biomedicines; 2022 Jan; 10(2):. PubMed ID: 35203419
[TBL] [Abstract][Full Text] [Related]
7. Genetic aberrations and survival in plasma cell leukemia.
Tiedemann RE; Gonzalez-Paz N; Kyle RA; Santana-Davila R; Price-Troska T; Van Wier SA; Chng WJ; Ketterling RP; Gertz MA; Henderson K; Greipp PR; Dispenzieri A; Lacy MQ; Rajkumar SV; Bergsagel PL; Stewart AK; Fonseca R
Leukemia; 2008 May; 22(5):1044-52. PubMed ID: 18216867
[TBL] [Abstract][Full Text] [Related]
8. Genetic profile of primary plasma cell leukemia in Korea: comparison with plasma cell myeloma.
Lee Y; Yun J; Jeong D; Ryu S; Kwon SR; Yun H; Kim SM; Park JH; Lee DS
Leuk Lymphoma; 2022 Feb; 63(2):385-394. PubMed ID: 34592901
[TBL] [Abstract][Full Text] [Related]
9. Plasma cell leukemia: a rare condition.
Jiménez-Zepeda VH; Domínguez VJ
Ann Hematol; 2006 Apr; 85(4):263-7. PubMed ID: 16416115
[TBL] [Abstract][Full Text] [Related]
10. [A primitive plasma cell leukemia with immunoglobulin (Ig) E].
Rachidi M; Lazarian G; Letestu R; Lusina D; Desbene C; Vidal V; Eclache V; Baran-Marszak F; Cymbalista F; Fleury C
Ann Biol Clin (Paris); 2019 Oct; 77(5):557-561. PubMed ID: 31512579
[TBL] [Abstract][Full Text] [Related]
11. Treatment with bortezomib-based regimens improves overall response and predicts for survival in patients with primary or secondary plasma cell leukemia: Analysis of the Greek myeloma study group.
Katodritou E; Terpos E; Kelaidi C; Kotsopoulou M; Delimpasi S; Kyrtsonis MC; Symeonidis A; Giannakoulas N; Stefanoudaki A; Christoulas D; Chatziaggelidou C; Gastari V; Spyridis N; Verrou E; Konstantinidou P; Zervas K; Dimopoulos MA
Am J Hematol; 2014 Feb; 89(2):145-50. PubMed ID: 24123068
[TBL] [Abstract][Full Text] [Related]
12. [Plasma cell leukemia: a highly aggressive monoclonal gammopathy with a very poor prognosis].
Jurczyszyn A; Zawirska D; Skotnicki AB
Przegl Lek; 2011; 68(6):320-5. PubMed ID: 22039670
[TBL] [Abstract][Full Text] [Related]
13. Plasma cell leukemia: A review of the molecular classification, diagnosis, and evidenced-based treatment.
Gowin K; Skerget S; Keats JJ; Mikhael J; Cowan AJ
Leuk Res; 2021 Dec; 111():106687. PubMed ID: 34425325
[TBL] [Abstract][Full Text] [Related]
14. A successful case of venetoclax-based therapy in relapsed/refractory secondary plasma cell leukemia.
Kupsh A; Arnall J; Voorhees P
J Oncol Pharm Pract; 2020 Jul; 26(5):1274-1278. PubMed ID: 31865846
[TBL] [Abstract][Full Text] [Related]
15. Primary plasma cell leukemia occuring in the young.
Raj RS; Najeeb S; Aruna R; Pavithran K; Thomas M
Indian J Cancer; 2003; 40(3):116-7. PubMed ID: 14716116
[TBL] [Abstract][Full Text] [Related]
16. Primary plasma cell leukemia in the era of new drugs: has something changed?
Musto P; Pagano L; Petrucci MT; Morabito F; Caravita T; Di Raimondo F; Baldini L; Tosi P; Bringhen S; Offidani M; Omede' P; Neri A; D'Auria F; Bochicchio GB; Cavo M; Boccadoro M; Palumbo A
Crit Rev Oncol Hematol; 2012 May; 82(2):141-9. PubMed ID: 21719304
[TBL] [Abstract][Full Text] [Related]
17. Plasma cell leukemia: a highly aggressive monoclonal gammopathy with a very poor prognosis.
Jimenez-Zepeda VH; Dominguez-Martinez VJ
Int J Hematol; 2009 Apr; 89(3):259-268. PubMed ID: 19326058
[TBL] [Abstract][Full Text] [Related]
18. Therapeutic advances in the treatment of primary plasma cell leukemia: a focus on hematopoietic cell transplantation.
Nishihori T; Abu Kar SM; Baz R; Alsina M; Harousseau JL; Kharfan-Dabaja MA
Biol Blood Marrow Transplant; 2013 Aug; 19(8):1144-51. PubMed ID: 23416092
[TBL] [Abstract][Full Text] [Related]
19. Single-center experience of patients with plasma cell leukemia in the era of new therapeutics.
Dampmann M; Flossdorf S; Keyl J; Reinhardt HC; Hanoun C
Acta Haematol; 2024 May; ():. PubMed ID: 38763126
[TBL] [Abstract][Full Text] [Related]
20. Genomics of Plasma Cell Leukemia.
Rojas EA; Gutiérrez NC
Cancers (Basel); 2022 Mar; 14(6):. PubMed ID: 35326746
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
